Anti-CTLA-4 [CP-675,206 (Tremelimumab, 11.2.1)]

Absolute Antibody

Anti-CTLA-4 [CP-675,206 (Tremelimumab, 11.2.1)]

7

Formerly known as ticilimumab, this Antibody is a fully human anti-huCTLA4 antagonist. It binds human and cycynomolgus monkey CTLA4 in flow cytometric analysis. It binds immobilized human and monkey CTLA4-Ig with average affinities of 0.28 and 0.98 nM, respectively. It is also reported that this antibody does not induce release of cytokines and also does not bind to human leukocyte Fc receptors. It blocks binding of human CTLA4-Ig to immobilized B7.1 and B7.2 with average IC50 values of 0.65 and 0.50 nM in competition binding studies. It was reported to enhance IL-2 and interferon-gamma production in human T cell blasts stimulated with B7-positive Raji cells and also enhanced IL-2 production in a concentration dependent manner in human and cynomolgus monkey whole blood (WB) and peripheral blood mononuclear cells (PBMC) stimulated with staphylococcal enterotoxin A (SEA) superantigen (Hansen et al, 2004). Phase I clinical trial with patients having advanced solid malignancies revealed that this antibody was safe and well tolerated and the related autoimmunity caused is reversible (Camacho et al., 2004). Phase 1 clinical trials in patients with advanced melanoma suggested that this antibody can be safely administered in a recommended dosage of 10 mg/kg every month and has antitumor activity in melanoma at monthly doses consistent with prolonged CTLA4 blockade (Ribas et al., 2005). It is also reported that therapy with this antibody reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (Reuben et al., 2005).

Flow Cytometry, ELISA, Neutralisation/Blocking

FC, Block, ELISA

Research Use Only

Monoclonal

CP-675,206 (Tremelimumab, 11.2.1)

CTLA4

cytotoxic T-lymphocyte associated protein 4

ALPS5; CD; CD152; celiac disease 3; CELIAC3; CTLA-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte-associated serine esterase-4; GRD4; GSE; IDDM12; insulin-dependent diabetes mellitus 12; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Human

IgG1

Cytotoxic T-lymphocyte protein 4

This reformatted human antibody was made using the variable domain sequences of the original Human IgG2 format, for improved compatibility with existing reagents, assays and techniques.

Human, cynomolgus monkey

The original antibody was generated by immunizing XenoMouse mice with cells expressing human CTLA-4 recombinantly.

-20°C,2°C to 8°C

12352203